Aier(SZ:300015) Zheng Quan Ri Bao Zhi Sheng·2026-01-23 10:42Core Viewpoint - The company has established a presence in Europe, Southeast Asia, and the United States, with overseas business showing strong growth and becoming a significant growth engine, contributing approximately 13% to total revenue [1] Group 1: Overseas Business Development - The overseas business revenue contribution is steadily increasing, indicating substantial growth potential in the future [1] - The company plans to adopt a tailored approach for overseas expansion, considering the market environment, healthcare systems, and regulatory requirements of different countries and regions [1] - The company aims to enhance its competitive advantages through scale effects in supply chain coordination, physician resource allocation, and brand influence as its overseas network expands [1] Group 2: Domestic and International Synergy - The company possesses mature experience in domestic ophthalmology diagnosis and treatment system construction and chain management, while having a solid practical foundation in overseas markets, particularly in presbyopia surgery [1] - By establishing an international communication and collaboration platform, the company seeks to achieve mutual empowerment of domestic and international resources, promoting overall business synergy [1]